Mike Lee actually said...

Pharmaceutical patents are extremely valuable and it's for good reason that they're valuable.

Opponents of reverse settlements have for several years argued that they're anti-competitive.

Both this recoupment of investment and these profits are jeopardized by lawsuits that are filed by generics.

Proponents of the agreements have argued that the agreements can never properly be considered anti-competitive.